Clinical Trial Update: Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating infliximab (Remicade) for treatment of dermatomyositis and polymyositis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis
• Polymyositis

Drugs mentioned

• Infliximab (infliximab)

Snippet

Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Conditions: Dermatomyositis, Polymyositis | Phase 2 | Status: COMPLETED